Media Advisory: Inte
Media Advisory: Interior Secretary Haaland, White House Climate Advisor Zaidi, Maryland Governor Moore to headline major offshore wind conference
March 27, 2023 10:03 ET | Business Network for Offshore Wind
Baltimore, March 27, 2023 (GLOBE NEWSWIRE) -- The tenth annual International Offshore Wind Partnering Forum (IPF), hosted by the Business Network for Offshore Wind, will kick off this Tuesday, March...
Interior Secretary H
Interior Secretary Haaland, White House Climate Advisor Zaidi, Maryland Governor Moore to Headline 2023 International Offshore Wind Partnering Forum
March 14, 2023 08:30 ET | Business Network for Offshore Wind
Baltimore, March 14, 2023 (GLOBE NEWSWIRE) -- The Business Network for Offshore Wind today announced U.S. Secretary of the Interior Deb Haaland, White House National Climate Advisor Ali Zaidi, and...
logo.jpg
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
February 24, 2023 07:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
February 17, 2023 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
Insilico Medicine Re
Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis
February 08, 2023 09:00 ET | InSilico Medicine
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023 16:00 ET | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
硕迪生物宣布经增发的首次公开募股的定价
February 02, 2023 20:59 ET | Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02, 2023 19:41 ET | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
January 17, 2023 01:00 ET | Kinarus Therapeutic Holding AG
 KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...